Home
Clinical Resources Search
PQI: Medication Induced Hand-Foot Syndrome

Medication Induced Hand-Foot Syndrome

Download PQI pdf

Last Updated: September 22, 2023

By: Jonas Congelli, RPh

About this PQI

The goal of this PQI is to discuss prevention and management of Hand-Foot Syndrome.

More About This PQI

PQI:

Managing-TKI-Induced-Hand-Foot-Skin-Reaction_PQI_NCODA pdf

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Frequently Searched

Supported by

Medication Induced Hand-Foot Syndrome

About this PQI

More About This PQI

PQI:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Encorafenib (Braftovi) + Cetuximab (Erbitux) + FOLFIRI for BRAF V600E-Positive Metastatic Colorectal Cancer

PQI: Reflex Biomarker Testing in Metastatic Colorectal Cancer: Implementing BRAF and MSI Assessment

PQI: Amivantamab and Hyaluronidase plus Lazertinib Patient Management

PQI: Belantamab Mafodotin (Blenrep) for the Management of Multiple Myeloma

PQI in Action: Capivasertib (Truqap) Patient Management

PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

PQI in Action: Darolutamide (Nubeqa)

PQI in Action: Zolbetuximab (Vyloy) for Gastroesophageal Cancers

S10 E13: Oncology Unfiltered: AI and the Future of Cancer Care

S10 E12: Inside GU Oncology with Uromigos Co-Host

S10 E10: Clearing the Fog: A Clinical Look at Chemo Brain

S10 E11: Your Best Meeting Ever

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Bi-Specific

Treatment Support Kit: Mirdametinib

Treatment Support Kit: Abemaciclib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Understanding Hand-Foot Syndrome (HFS) and Hand-Foot Skin Reaction (HFSR) During Cancer Treatment

PQI: Managing TKI-Induced Hand-Foot Skin Reaction

Understanding Hand-Foot Syndrome (HFS) and Hand-Foot Skin Reaction (HFSR) During Cancer Treatment

PQI: Managing TKI-Induced Hand-Foot Skin Reaction

Cabozantinib and Nivolumab

Cabozantinib

Treatment Support Kit: Cabozantinib

PQI: Cabozantinib (Cabometyx®)

Cabozantinib and Nivolumab

Cabozantinib

Treatment Support Kit: Cabozantinib

PQI: Cabozantinib (Cabometyx®)

Pembrolizumab, Trastuzumab, and CAPOX

Trastuzumab, Capecitabine, and Cisplatin

Pembrolizumab, Trastuzumab, Capecitabine, and Cisplatin

Capecitabine and Oxaliplatin with Radiation Therapy

Sorafenib

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Regorafenib

PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Sorafenib

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Regorafenib

PQI: Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Filgrastim

Pegfilgrastim

Pamidronate

How to Categorize Cancer Drug Therapy

Pembrolizumab, Trastuzumab, and CAPOX

Trastuzumab, Capecitabine, and Cisplatin

Pembrolizumab, Trastuzumab, Capecitabine, and Cisplatin

Capecitabine and Oxaliplatin with Radiation Therapy

Ibrutinib and BR

Ibrutinib and Obinutuzumab

Vepdegestrant

Sirolimus